Next Generation Antibody Drug: Core Growth Enabler in the Rising Adoption Of Personalized Medicine Fueling The Growth Of The Market Due To Advancements In Genomic Sequencing Market, 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Next Generation Antibody Drug Industry Market Size Be by 2025?
The market size for the next generation antibody drug has experienced a substantial expansion in recent years. It is expected to escalate from $14.26 billion in 2024 to $16.4 billion in 2025, representing a compound annual growth rate (CAGR) of 15.0%. The advancement during the historical period can be associated with the rising demand for targeted therapies, increasing incidence of cancer, and the expanding adoption of immuno-oncology therapies. Additionally, the heightened focus on autoimmune diseases and growing regulatory backing has also contributed to the growth.

What's the Long-Term Growth Forecast for the Next Generation Antibody Drug Market Size Through 2029?
The market size of next-generation antibody drugs is anticipated to experience swift expansion in the coming years, projecting to reach "$29.08 billion by 2029 with a compound annual growth rate (CAGR) of 15.4%. The escalation during the prediction period can be credited to the growing requirement for custom-made medicine, enlarging drug pipeline developments, heightened healthcare consciousness, amplified research partnerships, and a burgeoning elderly population. Notable developments forecasted for this period encompass progress in antibody-drug conjugates, technological progress in bispecific antibodies, the inclusion of next-generation sequencing, breakthroughs in protein engineering, and advancements in gene therapy integration.

View the full report here:
https://www.thebusinessresearchcompany.com/report/next-generation-antibody-drug-global-market-report

What Are the Key Growth Drivers Fueling the Next Generation Antibody Drug Market Expansion?
The escalating emphasis on personalized medicine is predicted to drive the expansion of the next-generation antibody-drug market. Personalized medicine is a health strategy that is custom-made to suit each patient's unique genetic, environmental, and lifestyle attributes, guaranteeing more targeted and efficient therapies. Such personalized medicine's surge can be chalked up to progress in genomic sequencing, allowing for a highly accurate diagnosing and strategic treatment. Next-generation antibodies drugs act as catalysts in this process, by enabling the formulation of targeted therapies, which conform to each patient's unique genetic composition and disease traits. This improves efficacy and reduces harmful side effects. For example, in February 2024, the Personalized Medicine Coalition, which is an organization based in the US, that advocates for the utilization of personalized medicine, reported that the United States Food and Drug Administration (FDA) authorized 16 new tailored treatments for patients with rare diseases in 2023, a significant increase from the 6 approved in the previous year, 2022. Thus, the mounting emphasis on personalized medicine propels the growth of the next-generation antibody drug market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24335&type=smp

What Long-Term Trends Will Define the Future of the Next Generation Antibody Drug Market?
Leading firms active in the upcoming generation of antibody drug market are committed to conceptualizing groundbreaking solutions such as antibody-drug conjugates. This focus is aimed at bolstering targeted cancer treatments, elevating therapeutic effectiveness, and mitigating systemic toxicity. An antibody-drug conjugate (ADC) proficiently connects a monoclonal antibody with a cytotoxic drug through a linker. This coupling allows for the particular delivery of the drug to cancer cells, while limiting harm to healthy tissues. For example, in January 2024, the BioNTech SE, a biotech firm from Germany, joined forces with Duality Biologics (Suzhou) Co. Ltd., a China-based pharma company. Their collaboration was granted a Fast Track designation by the U.S. Food and Drug Administration (FDA) for their forthcoming ADC candidate, BNT325/DB-1305. This ADC candidate optimizes treatment for patients suffering from platinum-resistant ovarian cancer. The drug leverages DualityBio's novel DITAC (Duality Immune Toxin Antibody Conjugates) platform, which synergistically merges a potent cytotoxic payload with a monoclonal antibody. This integrated approach leads to the precision delivery of treatment directly to the cancer cells. The unique feature of BNT325/DB-1305 is its potential to exactly target cancer cells, thereby reducing damage to healthy tissues. This attribute positions it as a crucial advantage in enhancing treatment success and lessening side effects.

How Is the Next Generation Antibody Drug Market Segmented?
The next generation antibody drug market covered in this report is segmented -

1) By Product Type: Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Types
2) By Mechanism Of Action: Checkpoint Inhibitors, Immune Modulators, Receptor Blockers, Targeted Cytotoxic Agents, Neutralizing Antibodies
3) By Delivery Method: Intravenous (IV) Administration, Subcutaneous Administration, Intramuscular Administration, Oral Formulations, Transdermal Delivery Systems
4) By Application: Oncology, Autoimmune Diseases, Infectious Diseases, Other Applications
5) By End User: Hospitals, Research Institutes, Specialty Clinics, Other End Users

Subsegments:
1) By Monoclonal Antibodies: Human Monoclonal Antibodies, Murine Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies
2) By Bispecific Antibodies: Checkpoint Inhibitor-Based Bispecifics, Bispecific Antibodies For Cytokine Modulation, Bispecific Antibodies With Extended Half-Life Technologies
3) By Antibody-Drug Conjugates: Cleavable Linker Antibody-Drug Conjugates, Non-Cleavable Linker Antibody-Drug Conjugates, Site-Specific Conjugated Antibody-Drug Conjugates

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24335&type=smp

Which Companies Are Leading the Charge in Next Generation Antibody Drug Market Innovation?
Major companies operating in the next generation antibody drug market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics Co. Ltd., WuXi Biologics Inc., Akeso Inc., Xencor Inc., ImmunoGen Inc., Philogen S.p.A., Telix Pharmaceuticals Limited, Actinium Pharmaceuticals Inc.

Which Regions Are Leading the Global Next Generation Antibody Drug Market in Revenue?
North America was the largest region in the next generation antibody drug market in 2024. The regions covered in the next generation antibody drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24335

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.